X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ORCHID PHARMA LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ORCHID PHARMA LTD SANOFI INDIA/
ORCHID PHARMA LTD
 
P/E (TTM) x 33.7 -0.5 - View Chart
P/BV x 6.4 0.4 1,763.0% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ORCHID PHARMA LTD
Sep-13
SANOFI INDIA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs4,560194 2,350.5%   
Low Rs4,40035 12,571.4%   
Sales per share (Unadj.) Rs1,028.5276.5 372.0%  
Earnings per share (Unadj.) Rs129.0-79.2 -162.8%  
Cash flow per share (Unadj.) Rs186.0-43.5 -428.0%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.653.9 1,397.2%  
Shares outstanding (eoy) m23.0370.45 32.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.40.4 1,051.8%   
Avg P/E ratio x34.7-1.4 -2,403.2%  
P/CF ratio (eoy) x24.1-2.6 -914.1%  
Price / Book Value ratio x5.92.1 280.0%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1748,067 1,279.0%   
No. of employees `0003.62.8 129.4%   
Total wages/salary Rs m3,5922,527 142.1%   
Avg. sales/employee Rs Th6,537.76,956.1 94.0%   
Avg. wages/employee Rs Th991.4902.5 109.9%   
Avg. net profit/employee Rs Th819.8-1,993.0 -41.1%   
INCOME DATA
Net Sales Rs m23,68619,477 121.6%  
Other income Rs m708407 173.9%   
Total revenues Rs m24,39419,884 122.7%   
Gross profit Rs m5,2811,103 479.0%  
Depreciation Rs m1,3132,519 52.1%   
Interest Rs m155,227 0.3%   
Profit before tax Rs m4,661-6,236 -74.7%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m1,691-125 -1,350.6%   
Profit after tax Rs m2,970-5,580 -53.2%  
Gross profit margin %22.35.7 393.8%  
Effective tax rate %36.32.0 1,807.1%   
Net profit margin %12.5-28.7 -43.8%  
BALANCE SHEET DATA
Current assets Rs m15,67311,014 142.3%   
Current liabilities Rs m6,67832,060 20.8%   
Net working cap to sales %38.0-108.1 -35.1%  
Current ratio x2.30.3 683.2%  
Inventory Days Days7695 80.1%  
Debtors Days Days2234 66.5%  
Net fixed assets Rs m8,09829,440 27.5%   
Share capital Rs m230705 32.7%   
"Free" reserves Rs m17,0882,043 836.6%   
Net worth Rs m17,3563,800 456.7%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m25,40046,510 54.6%  
Interest coverage x311.7-0.2 -161,419.4%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.90.4 222.7%   
Return on assets %11.8-0.8 -1,546.2%  
Return on equity %17.1-146.9 -11.7%  
Return on capital %26.9-3.7 -721.4%  
Exports to sales %24.537.9 64.7%   
Imports to sales %28.022.6 123.7%   
Exports (fob) Rs m5,8017,378 78.6%   
Imports (cif) Rs m6,6274,406 150.4%   
Fx inflow Rs m7,1457,513 95.1%   
Fx outflow Rs m6,8465,649 121.2%   
Net fx Rs m2991,865 16.0%   
CASH FLOW
From Operations Rs m3,2261,682 191.8%  
From Investments Rs m-1,555-9,860 15.8%  
From Financial Activity Rs m-1,8186,644 -27.4%  
Net Cashflow Rs m-147-1,535 9.6%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 4.6 313.0%  
FIIs % 14.6 3.3 442.4%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.5 55.3 19.0%  
Shareholders   15,184 84,811 17.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 20, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS